scholarly journals In vivo delivery of miRNAs for cancer therapy: Challenges and strategies

2015 ◽  
Vol 81 ◽  
pp. 128-141 ◽  
Author(s):  
Yunching Chen ◽  
Dong-Yu Gao ◽  
Leaf Huang
Keyword(s):  
Cancer Therapy ◽  
In Vivo Delivery ◽  
Challenges And Strategies

In Vivo Delivery of Silica Nanorattle Encapsulated Docetaxel for Liver Cancer Therapy with Low Toxicity and High Efficacy

ACS Nano ◽  
2010 ◽  
Vol 4 (11) ◽  
pp. 6874-6882 ◽  
Author(s):  
Linlin Li ◽  
Fangqiong Tang ◽  
Huiyu Liu ◽  
Tianlong Liu ◽  
Nanjing Hao ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Liver Cancer ◽  
High Efficacy ◽  
Low Toxicity ◽  
Silica Nanorattle ◽  
In Vivo Delivery

Ultrasound-Guided in Vivo Delivery of Cold Plasma Gas for Cancer Therapy via Microbubbles

2021 ◽  
Author(s):  
Wenyu Guo ◽  
Shuo Huang ◽  
Jie Dang ◽  
Jian An ◽  
Feihong Dong ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Cold Plasma ◽  
Ultrasound Guided ◽  
In Vivo Delivery

Comprehensively enhanced delivery cascade by transformable beaded nanofibrils for pancreatic cancer therapy

Nanoscale ◽  
2021 ◽  
Author(s):  
Qinglin Sheng ◽  
Ting Li ◽  
Xian Tang ◽  
Wei Zhao ◽  
Rong Guo ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Tumor Therapy ◽  
Pancreatic Cancer Therapy ◽  
Delivery Efficiency ◽  
In Vivo Delivery

Facing the barriers in each step of the in vivo delivery cascade, the low drug delivery efficiency remains a thorny problem in tumor therapy. Although recently the nanofibril drug delivery...

scholarly journals In Vivo Delivery of Silica Nanorattle Encapsulated Docetaxel for Liver Cancer Therapy with Low Toxicity and High Efficacy

ACS Nano ◽  
2010 ◽  
Vol 5 (1) ◽  
pp. 679-679 ◽  
Author(s):  
Linlin Li ◽  
Fangqiong Tang ◽  
Huiyu Liu ◽  
Tianlong Liu ◽  
Nanjing Hao ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Liver Cancer ◽  
High Efficacy ◽  
Low Toxicity ◽  
Silica Nanorattle ◽  
In Vivo Delivery

Potential use of RNA interference in cancer therapy

2010 ◽  
Vol 12 ◽  
Author(s):  
Connor Phalon ◽  
Donald D. Rao ◽  
John Nemunaitis
Keyword(s):  
Clinical Trials ◽  
Rna Interference ◽  
Cancer Therapy ◽  
Delivery Systems ◽  
Specific Gene ◽  
Systemic Delivery ◽  
Therapeutic Approaches ◽  
In Vivo Delivery ◽  
Potential Use

RNA interference (RNAi) is an evolutionary conserved mechanism for specific gene silencing. This mechanism has great potential for use in targeted cancer therapy. Understanding the RNAi mechanism has led to the development of several novel RNAi-based therapeutic approaches currently in the early phases of clinical trials. It remains difficult to effectively deliver the nucleic acids required in vivo to initiate RNAi, and intense effort is under way in developing effective and targeted systemic delivery systems for RNAi. Description of in vivo delivery systems is not the focus of this review. In this review, we cover the rationale for pursuing personalised cancer therapy with RNAi, briefly review the mechanism of each major RNAi therapeutic technique, summarise and sample recent results with animal models applying RNAi for cancer, and provide an update on current clinical trials with RNAi-based therapeutic agents for cancer therapy. RNAi-based cancer therapy is still in its infancy, and there are numerous obstacles and issues that need to be resolved before its application in personalised therapy focusing on patient-cancer-specific targets can become standard cancer treatment, either alone or in combination with other treatments.

scholarly journals Burst of Corneal Dendritic Cells during Trastuzumab and Paclitaxel Treatment

Diagnostics ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 838
Author(s):  
Katharina A. Sterenczak ◽  
Nadine Stache ◽  
Sebastian Bohn ◽  
Stephan Allgeier ◽  
Bernd Köhler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dendritic Cells ◽  
Cancer Therapy ◽  
Adverse Effects ◽  
Laser Scanning Microscopy ◽  
Sensory Nerves ◽  
Confocal Laser ◽  
Corneal Nerves ◽  
Over Time

During breast cancer therapy, paclitaxel and trastuzumab are both associated with adverse effects such as chemotherapy-induced peripheral neuropathy and other systemic side effects including ocular complications. Corneal nerves are considered part of the peripheral nervous system and can be imaged non-invasively by confocal laser scanning microscopy (CLSM) on the cellular level. Thus, in vivo CLSM imaging of structures of the corneal subbasal nerve plexus (SNP) such as sensory nerves or dendritic cells (DCs) can be a powerful tool for the assessment of corneal complications during cancer treatment. During the present study, the SNP of a breast cancer patient was analyzed over time by using large-scale in vivo CLSM in the course of paclitaxel and trastuzumab therapy. The same corneal regions could be re-identified over time. While the subbasal nerve morphology did not alter significantly, a change in dendritic cell density and an additional local burst within the first 11 weeks of therapy was detected, indicating treatment-mediated corneal inflammatory processes. Ocular structures such as nerves and dendritic cells could represent useful biomarkers for the assessment of ocular adverse effects during cancer therapy and their management, leading to a better visual prognosis.

scholarly journals Current Stimuli-Responsive Mesoporous Silica Nanoparticles for Cancer Therapy

Pharmaceutics ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 71
Author(s):  
Thashini Moodley ◽  
Moganavelli Singh
Keyword(s):  
Cancer Therapy ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Therapeutic Agents ◽  
Metal Species ◽  
Stimuli Responsive ◽  
Combination Drug ◽  
Incidence And Mortality

With increasing incidence and mortality rates, cancer remains one of the most devastating global non-communicable diseases. Restricted dosages and decreased bioavailability, often results in lower therapeutic outcomes, triggering the development of resistance to conventionally used drug/gene therapeutics. The development of novel therapeutic strategies using multimodal nanotechnology to enhance specificity, increase bioavailability and biostability of therapeutics with favorable outcomes is critical. Gated vectors that respond to endogenous or exogenous stimuli, and promote targeted tumor delivery without prematurely cargo loss are ideal. Mesoporous silica nanoparticles (MSNs) are effective delivery systems for a variety of therapeutic agents in cancer therapy. MSNs possess a rigid framework and large surface area that can incorporate supramolecular constructs and varying metal species that allow for stimuli-responsive controlled release functions. Its high interior loading capacity can incorporate combination drug/gene therapeutic agents, conferring increased bioavailability and biostability of the therapeutic cargo. Significant advances in the engineering of MSNs structural and physiochemical characteristics have since seen the development of nanodevices with promising in vivo potential. In this review, current trends of multimodal MSNs being developed and their use in stimuli-responsive passive and active targeting in cancer therapy will be discussed, focusing on light, redox, pH, and temperature stimuli.

Sign in / Sign up

Export Citation Format

Share Document